Feasibility of pharmacy-initiated pharmacogenetic screening for CYP2D6 and CYP2C19

European Journal of Clinical Pharmacology

Volumn 68, Issue 4, 2012, Pages 363-370

  Swen, J J ^a   Van Der Straaten, T ^a   Wessels, J A M ^a   Bouvy, M L ^b   Vlassak, E E W ^c   Assendelft, W J J ^a   Guchelaar, H J ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UTRECHT UNIVERSITY   (Netherlands)

^c Apotheek de Schelft ^*  (Netherlands)

Author keywords

Cytochrome P 450 CYP2C19; Cytochrome P 450 CYP2D6; Pharmacogenetics; Primary health care

Indexed keywords

ACENOCOUMAROL; AMITRIPTYLINE; AZATHIOPRINE; CITALOPRAM; CLOPIDOGREL; CODEINE; DNA; ESOMEPRAZOLE; ESTROGEN; IMIPRAMINE; METOPROLOL; NORTRIPTYLINE; OMEPRAZOLE; OXYCODONE; PANTOPRAZOLE; PAROXETINE; PHENPROCOUMON; SERTRALINE; TRAMADOL;

ADULT; AGED; ARTICLE; CYP2C19 GENE; CYP2D6 GENE; EVIDENCE BASED MEDICINE; FEMALE; GENE; GENETIC SCREENING; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; PHARMACY INITIATED PHARMACOGENETIC SCREENING; PHENOTYPE; POLYPHARMACY; PRACTICE GUIDELINE; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; SALIVA ANALYSIS;

AGED; AGED, 80 AND OVER; ARYL HYDROCARBON HYDROXYLASES; COMMUNITY PHARMACY SERVICES; CYTOCHROME P-450 CYP2D6; DNA; FEMALE; GENETIC TESTING; GENOTYPE; HUMANS; MALE; MIDDLE AGED; POLYPHARMACY; SALIVA;

EID: 84860267825     PISSN: 00316970     EISSN: 14321041     Source Type: Journal    
DOI: 10.1007/s00228-011-1130-4     Document Type: Article

References (24)

1. Altman RB (2011) Pharmacogenomics: "noninferiority" is sufficient for initial implementation. Clin Pharmacol Ther 89:348-350
2. Wang L, McLeod HL, Weinshilboum RM (2011) Genomics and drug response. N Engl J Med 364:1144-1153
3. Ashley EA, Butte AJ, Wheeler MT, Chen R, Klein TE, Dewey FE, Dudley JT, Ormond KE, Pavlovic A, Morgan AA, Pushkarev D, Neff NF, Hudgins L, Gong L, Hodges LM, Berlin DS, Thorn CF, Sangkuhl K, Hebert JM, Woon M, Sagreiya H, Whaley R, Knowles JW, Chou MF, Thakuria JV, Rosenbaum AM, Zaranek AW, Church GM, Greely HT, Quake SR, Altman RB (2010) Clinical assessment incorporating a personal genome. Lancet 375:1525-1535
4. Phillips KA, Veenstra DL, Oren E, Lee JK, Sadee W (2001) Potential role of pharmacogenomics in reducing adverse drug reactions: a systematic review. JAMA 286:2270-2279 (Pubitemid 33063150)
5. Grice GR, Seaton TL, Woodland AM, McLeod HL (2006) Defining the opportunity for pharmacogenetic intervention in primary care. Pharmacogenomics 7:61-65
6. Van Puijenbroek PE, Conemans J, van Grootheest K (2009) Spontaneous ADR reports as a trigger for pharmacogenetic research: a prospective observational study in the Netherlands. Drug Saf 32:255-264
7. Relling MV, Klein TE (2011) CPIC: Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network. Clin Pharmacol Ther 89:464-467
8. Swen JJ, Nijenhuis M, de Boer A, Grandia L, Maitland-van der Zee AH, Mulder H, Rongen GA, van Schaik RH, Schalekamp T, Touw DJ, van der Weide J, Wilffert B, Deneer VH, Guchelaar HJ (2011) Pharmacogenetics: from bench to byte- an update of guidelines. Clin Pharmacol Ther 89:662-673
9. Relling MV, Gardner EE, Sandborn WJ, Schmiegelow K, Pui CH, Yee SW, Stein CM, Carrillo M, Evans WE, Klein TE (2011) Clinical Pharmacogenetics Implementation Consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing. Clin Pharmacol Ther 89:387-391
10. Buurma H, Bouvy ML, De Smet PA, Floor-Schreudering A, Leufkens HG, Egberts AC (2008) Prevalence and determinants of pharmacy shopping behaviour. J Clin Pharm Ther 33:17-23
11. Hansten P, Horn J (2004) The top 100 drug interactions. A guide to patient management H&H Publications
12. Cavallari L, Ellingrod V, Kolesar J (2006) Lexi-Comp's Pharmacogenomics Handbook, 2nd edition Edition, Lexi Comp
13. Kirchheiner J, Nickchen K, Bauer M, Wong ML, Licinio J, Roots I, Brockmoller J (2004) Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response. Mol Psychiatry 9:442-473 (Pubitemid 38903502)
14. Mega JL, Close SL, Wiviott SD, Shen L, Hockett RD, Brandt JT, Walker JR, Antman EM, Macias W, Braunwald E, Sabatine MS (2009) Cytochrome p-450 polymorphisms and response to clopidogrel. NEnglJMed 360:354-362
15. Ho PM, Maddox TM, Wang L, Fihn SD, Jesse RL, Peterson ED, Rumsfeld JS (2009) Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA 301:937-944
16. Swen JJ, Wilting I, de Goede AL, Grandia L, Mulder H, Touw DJ, de Boer A, Conemans JM, Egberts TC, Klungel OH, Koopmans R, van der Weide J, Wilffert B, Guchelaar HJ, Deneer VH (2008) Pharmacogenetics: from bench to byte. Clin Pharmacol Ther 83:781-787 (Pubitemid 351556025)
17. Rogausch A, Prause D, Schallenberg A, Brockmoller J, Himmel W(2006) Patients' and physicians' perspectives on pharmacogenetic testing. Pharmacogenomics 7:49-59
18. van Wieren-de Wijer DB, Maitland-van der Zee AH, de Boer A, Kroon AA, de Leeuw PW, Schiffers P, Janssen RG, Psaty BM, van Duijn CM, Stricker BH, Klungel OH (2009) Reasons for nonresponse in observational pharmacogenetic research. PharmacoepidemiolDrug Saf 18:665-671
19. Borges S, Desta Z, Li L, Skaar TC, Ward BA, Nguyen A, Jin Y, Storniolo AM,NikoloffDM,Wu L, HillmanG, Hayes DF, Stearns V, Flockhart DA (2006) Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment. Clin Pharmacol Ther 80:61-74 (Pubitemid 43946844)
20. Tamminga WJ, Wemer J, Oosterhuis B, de Zeeuw RA, de Leij LF, Jonkman JH (2001) The prevalence of CYP2D6 and CYP2C19 genotypes in a population of healthy Dutch volunteers. Eur J Clin Pharmacol 57:717-722 (Pubitemid 34031264)
21. Sachse C, Brockmoller J, Bauer S, Roots I (1997) Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am J Hum Genet 60:284-295 (Pubitemid 27058401)
22. de Leon J, Susce MT, JohnsonM, Hardin M, Maw L, Shao A, Allen AC, Chiafari FA, Hillman G, Nikoloff DM (2009) DNA microarray technology in the clinical environment: the AmpliChip CYP450 test for CYP2D6 and CYP2C19 genotyping. CNSSpectr 14:19-34
23. Rylander-Rudqvist T, Hakansson N, Tybring G, Wolk A (2006) Quality and quantity of saliva DNA obtained from the self-administrated oragene method-a pilot study on the cohort of Swedish men. Cancer Epidemiol Biomarkers Prev 15:1742-1745 (Pubitemid 44497113)
24. Evans WE, Relling MV (1999) Pharmacogenomics: translating functional genomics into rational therapeutics. Science 286:487-491